Startups
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Numerous top biopharma executives met recently in Manalapan, Florida for the R&D Leadership Summit. Although a wide range of topics were discussed, certain areas rose to the top as being of particular concern to industry leadership. Here’s a look at a few of those concerns.
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Arizona is not exactly the first place one thinks of when it comes to the life sciences. But, like many states and municipalities, Arizona and Phoenix, Arizona, are working hard to grow the life science industry. According to AZBio, bioscience companies in Arizona employed 25,686 people in 2016 in 1,310 individual businesses.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
Flagship Pioneering closed out a monster pool of funds to support a number of pioneering life science companies. Cambridge, Mass.-based Flagship secured $824 million in a new capital pool to boost companies that launch from its Flagship Labs incubator unit.
New York City, despite its size, population and access to venture capital and top academic institutions, is not a major center for life science startups. But recent reports suggest that may—at least a little bit—be changing.
The Minafin Group announces the launch of Minagro, a new global business unit dedicated to developing and marketing greener and safer ingredients for the crop care industry.
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
The company’s proprietary CRISPR-Cas tech platform is used to selectively and precisely eradicate target bacterial, but still leave the patient’s microbial community alone.
PRESS RELEASES